TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19368965
Drug: Budesonide/formoterol 200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 200/6 microg twice daily plus as-needed
Study: 19368965
Drug: Budesonide/formoterol 800/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 800/12 microg twice daily
Study: 16716321
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of prednisone (20 mg/d), aspirin (100 mg/d), folate (5 mg every second day), and progesterone (20 mg/d) for the first 12 weeks of gestation.
Study: 16716321
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of prednisone, aspirin, folate, and progesterone.
Study: 9134638
Drug: Anti-factor VIII
Normalized name: Anti-factor VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-factor VIII inhibitors (a-fVIII)
Study: 9134638
Drug: Lupus anticoagulants
Normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulants (LAs)
Study: 7934158
Drug: rhGM‐CSF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF with standard induction chemotherapy (TAD)
Study: 2849968
Drug: Pipecuronium 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium 0.07 mg kg‐1
Study: 29194612
Drug: Nanocurcumin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin therapy for 6 months
Study: 29194612
Drug: Nanocurcumin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin therapy
Study: 28753849
Drug: ODM-201 (200-1800mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-201 (200-1800mg, oral, twice daily)
Study: 25887096
Drug: Extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release mixed amphetamine salts (60 mg)
Study: 25887096
Drug: Extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release mixed amphetamine salts (80 mg)
Study: 17175661
Drug: Zemaira (study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zemaira (study drug)
Study: 17175661
Drug: Prolastin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin (control drug)
Study: 12547873
Drug: HIM2 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIM2 (1.0 mg/kg)
Study: 12547873
Drug: HIM2 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIM2 (0.5 and 1.0 mg/kg)
Study: 8938913
Drug: Clozapine 200
Normalized name: clozapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 200 mg/day (withdrawn abruptly)
Study: 1411636
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 single oral dose on day 8
Study: 1411636
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 and 120 mg/m2 single oral doses on days 8 and 15
Study: 1411636
Drug: 120 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/m2 and 240 mg/m2 single oral doses on days 8 and 15
Study: 1411636
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 single oral doses on 5 consecutive days from days 8 to 12
Study: 1411636
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 three times a day at 6-hour intervals on day 8
Study: 1411636
Drug: 240 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/m2 single oral dose
Study: 1411636
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses on 1 day or 5 consecutive days
Study: 30571332
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (eicosapentaenoic acid+docosahexaenoic acid; 8‐10 g for 2‐5 days preoperatively, and then 2 g/d postoperatively)
Study: 22574800
Drug: Behaviour Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour Therapy + Constructive Worry (BT + CW)
Study: 18801827
Drug: AVE1625 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE1625 (20 mg)
Study: 18556965
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice daily for 6 months)
Study: 16087013
Drug: Single 2.0‐g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2.0‐g dose of azithromycin microsphere formulation
Study: 16087013
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of levofloxacin, 500 mg/d
Study: 11577787
Drug: Optimized pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized pharmacotherapy for GAD
Study: 11577787
Drug: Agent with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent with demonstrated effectiveness for GAD
Study: 11577787
Drug: Adequate dosing
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate dosing and duration of treatment
Study: 11577787
Drug: Adjunctive strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive strategies for refractory patients
Study: 31972397
Drug: Creative music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative music therapy (CMT)
Study: 29574701
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel 12 mg
Study: 27364955
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg piragliatin twice daily
Study: 27364955
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg piragliatin twice daily
Study: 23611405
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Study: 23611405
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Study: 23611405
Drug: Concurrent chemotherapy/radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy/radiotherapy (CT/TRT) with docetaxel 20 mg/m² and carboplatin AUC 2 weekly plus 60 Gy TRT
Study: 23611405
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and concurrent CT/TRT
Study: 23611405
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy and concurrent CT/TRT
Study: 18287590
Drug: Carvedilol (32.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (32.9 +/- 3.5 mg)
Study: 18287590
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (96.4 +/- 15.9 mg)
Study: 11105738
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of enteric‐coated fluoxetine weekly
Study: 11105738
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of enteric‐coated fluoxetine weekly and 20 mg daily fluoxetine
Study: 9196864
Drug: Iloprost (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (5-day infusion at 2.0 ng/kg per minute for 8 hours per day, followed by a 1-day infusion every 6 weeks)
Study: 9196864
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily, oral slow-release formulation)
Study: 30253405
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for 6 months post-VIU
Study: 16326163
Drug: Pamphlet based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlet based on the FDA Tips for the Savvy Supplement User
Study: 11289500
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy alone (average TT: 22.2%)
Study: 11289500
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with antiplatelet agent (average TT: 20.9%)
Study: 1458789
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (3.6 g per day)
Study: 3881108
Drug: Aspirin 990
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 990 mg and dipyridamole 225 mg daily
Study: 24792139
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (SNAGs and PJM)
Study: 11125687
Drug: Intra-articular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ketamine 0.5 mg/kg diluted with saline up to 5 mL
Study: 11125687
Drug: Intra-muscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-muscular ketamine 0.5 mg/kg
Study: 11125687
Drug: Saline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 5 mL intra-articularly (control)
Study: 3526500
Drug: Leucine treatment
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine treatment
Study: 28121470
Drug: Wheatgrass (Triticum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheatgrass (Triticum aestivum L.) 3.5 g freeze-dried powder daily for 10 weeks
Study: 23832863
Drug: 0.3 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 µg/kg SPA (n = 8)
Study: 23832863
Drug: 0.45 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 µg/kg SPA (n = 8)
Study: 23832863
Drug: 0.3 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 µg/kg and 0.45 µg/kg SPA
Study: 19249698
Drug: Modified vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaginal hysterectomy method; details on dosage and duration not applicable.
Study: 19249698
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical methods; details on dosage and duration not applicable.
Study: 18666468
Drug: L-T4 (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T4 (1.7 ug/kg)
Study: 16479742
Drug: Polyhexamethylene biguanide
Normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexamethylene biguanide cream
Study: 10219333
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 mcg/kg subcutaneous injection daily from day 9 until neutrophil count exceeds 0.5 x 10(9)/l for 3 days)
Study: 10219333
Drug: G-CSF after
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF after second intensification
Study: 2114414
Drug: Lysine acetyl
Normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetyl salicylate (Aspergesic) 1.8 g t.d.s.
Study: 2114414
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg t.d.s.
Study: 26088042
Drug: Hydration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration group (increased water intake by 1 to 1.5 l/day)
Study: 24075206
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with intratracheal bolus administration of surfactant
Study: 21682970
Drug: Delamanid 100
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 100 mg daily for 14 days
Study: 21682970
Drug: Delamanid 200
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 200 mg daily for 14 days
Study: 21682970
Drug: Delamanid 300
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 300 mg daily for 14 days
Study: 21682970
Drug: Delamanid 400
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid 400 mg daily for 14 days
Study: 19183825
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention (drug therapy alone or combined with behavioral therapy) for 10 weeks
Study: 19183825
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after stopping therapy for 6 months
Study: 15572491
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (200-mcg tablet)
Study: 9859573
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (Abciximab, tirofiban, lamifiban, integrelin)
Study: 8089244
Drug: Chlorhexidine (0.12%)
Normalized name: chlorhexidine 12 MG
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 30 days starting 2 days after extraction
Study: 8089244
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution rinses for 30 days starting 2 days after extraction
Study: 28205255
Drug: Maternal antiretroviral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antiretroviral therapy (ART)
Study: 19097507
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (n = 32)
Study: 15998785
Drug: Medium dairy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dairy, increase calcium intake to approximately 1000-1100 mg/d
Study: 15998785
Drug: High dairy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy, increase calcium intake to approximately 1200-1300 mg/d
Study: 15998785
Drug: Control, continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control, continuous established (<800 mg/d) dietary calcium intake
Study: 7141392
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Study: 7141392
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Study: 29064743
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg QD + Metformin 1000 mg BID (COMBO)
Study: 29064743
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg BID (MET)
Study: 25495769
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound (PUS) therapy
Study: 25495769
Drug: Erythromycin phonophoresis
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin phonophoresis (EP) therapy
Study: 17136563
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream once daily for 4 weeks
Study: 17136563
Drug: Intramuscular alefacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular alefacept 15 mg for 12 weeks
Study: 12590402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirtazapine and amitriptyline
Study: 6384455
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO oral glucose-electrolyte solution containing 90 mmol of sodium per liter (Group A: 22 infants)
Study: 6384455
Drug: Oral glucose-electrolyte
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose-electrolyte solution containing 60 mmol of sodium per liter (Group B: 22 infants)
Study: 6384455
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous therapy (Group C: 21 infants)
Study: 29059263
Drug: Daily financial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals (4 or more checks per day, with 1 or more levels within the goal range of 70-180 mg/dL) during a 3-month intervention period.
Study: 29059263
Drug: Daily financial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals during a 3-month intervention period.
Study: 19650746
Drug: New inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: New inhibitors of the proton pump (potassium-competitive acid blockers)
Study: 19650746
Drug: Reflux inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflux inhibitors (GABA(B) receptor agonists and mGluR5 antagonists)
Study: 19650746
Drug: Visceral analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral analgesics and growth factors
Study: 14759379
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus niacin (mean daily dose 13 mg and 2.4 g, respectively)
Study: 9414969
Drug: Lactose (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (34 g per day)
Study: 9414969
Drug: Sucrose (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (34 g per day)
Study: 3716756
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg)
Study: 29791971
Drug: Collagenase Clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium histolyticum (CCH) treatment
Study: 26564457
Drug: Meibomian gland
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meibomian gland tube massage in addition to corticosteroid eye ointment and artificial tears
Study: 26564457
Drug: Corticosteroid eye
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid eye ointment and artificial tears
Study: 23700337
Drug: Repeated Exposure
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated Exposure (RE) group; 2 kJ/g; n = 32
Study: 23700337
Drug: Flavor-Flavor Learning
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-Flavor Learning (FFL) group; 2 kJ/g; n = 32
Study: 23700337
Drug: Flavor-Nutrient Learning
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-Nutrient Learning (FNL) group; 6 kJ/g; n = 31
Study: 10641042
Drug: Enteric-coated peppermint-caraway
Normalized name: Caraway Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Study: 10641042
Drug: Non-enteric-coated peppermint-caraway
Normalized name: Caraway Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Study: 8878595
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without 800 mg of ofloxacin (OFLO)
Study: 8878595
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600 mg of rifampin
Study: 8878595
Drug: Month-long standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Month-long standard regimen of multidrug therapy (MDT) for multibacillary leprosy
Study: 8878595
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of CLARI-MINO, with or without OFLO
Study: 1906152
Drug: hMGs following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hMGs following midluteal pre‐treatment with leuprolide
Study: 6506175
Drug: 39 mg
Normalized name: fiber 539 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39 mg elemental iron
Study: 6506175
Drug: 39 mg
Normalized name: fiber 539 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39 mg elemental iron plus 75 mg vitamin C
Study: 6506175
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin C daily
Study: 16086912
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy supplemental beam radiation (PSA <10 ng/ml)
Study: 16086912
Drug: 44 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 Gy supplemental beam radiation (PSA <10 ng/ml)
Study: 16086912
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy supplemental beam radiation (PSA >10 ng/ml)
Study: 16086912
Drug: 44 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 Gy supplemental beam radiation (PSA >10 ng/ml)
Study: 12150649
Drug: Adequate antidepressant
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antidepressant treatment
Study: 12150649
Drug: Adequate pharmacotherapy
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate pharmacotherapy
Study: 282073
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for hypertension
Study: 25569647
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (Group F)
Study: 17239279
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy with bicalutamide
Study: 17239279
Drug: Escalated-dose external-beam
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated-dose external-beam radiation therapy
Study: 12481147
Drug: L-arginine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (300 mg/kg)
Study: 9140680
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg orally once per day (max 20 mg once per day)
Study: 9140680
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg orally once per day (max 25 mg twice per day)
Study: 9140680
Drug: Lisinopril 5-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5-20 mg once daily